-
Mashup Score: 1FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease - 11 month(s) ago
The FDA’s approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 36FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease - 11 month(s) ago
The FDA’s approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
FDA approval of colchicine for coronary inflammation is expected to have a big impact on cardiac care and outcomes. #colchicine #atherosclerosis #pharma #cardiotwitter #cardiology #pharmacology https://t.co/WZfUxndJAK
-
-
Mashup Score: 10potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes - 12 month(s) ago
Abstract. In type 1 diabetes, average life expectancy is reduced by ˃10 years as compared with outside of diabetes. Residual cardiovascular risk defines high ca
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
RT @SABOURETCardio: #colchicine : potential impact on #MACE in #T1D. #Diabetes #Cardiotwitter https://t.co/7KxJpwzwPS
-
-
Mashup Score: 0
No significant differences in the risk of myocardial infarction and other cardiovascular events were observed between patients with gout who received colchicine and those who did not.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
The risk of revascularization, stroke, and myocardial infarction was not higher in patients with #gout treated with #colchicine compared with those who did not receive the drug: https://t.co/v5tvyeqDLK
-
-
Mashup Score: 0
No significant differences in the risk of myocardial infarction and other cardiovascular events were observed between patients with gout who received colchicine and those who did not.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
No significant differences in the risk of myocardial infarction and other cardiovascular events were observed between patients with #gout who received #colchicine and those who did not. https://t.co/zbrnbBtj0G
-
-
Mashup Score: 6
COP-AF is a large randomized and blinded trial designed to determine whether colchicine reduces the risk of perioperative AF or MINS in patients who have major noncardiac thoracic surgery.
Source: PubMedCategories: Cardiology News and Journals, Latest HeadlinesTweet-
RT @giovannilandoni: Now on Pubmed https://t.co/tQ8nuTUC94 Is #colchicine preventing #atrialfibrillation and #myocardialinjury #MINS in #…
-
-
Mashup Score: 7Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial - 1 year(s) ago
In people with painful hand osteoarthritis, treatment with 0·5 mg of colchicine twice day for 12 weeks did not effectively relieve pain, and treatment with colchicine was associated with more adverse events.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW RESEARCH—@AnnaDossing and colleagues report the results of the COLOR trial; #colchicine twice a day did not relieve #pain vs placebo in people with hand #osteoarthritis https://t.co/LfKTwVONGM https://t.co/jTBh076LZ6
-
-
Mashup Score: 3potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes - 1 year(s) ago
Abstract. In type 1 diabetes, average life expectancy is reduced by ˃10 years as compared with outside of diabetes. Residual cardiovascular risk defines high ca
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#colchicine : potential impact on #MACE in #T1D. #Diabetes #Cardiotwitter https://t.co/7KxJpwzwPS
-
-
Mashup Score: 0Examining the Characteristics of Colchicine-Induced Myelosuppression in Clinical Cases: A Systematic Review - 1 year(s) ago
Objective The use of colchicine has been associated with varying degrees of myelosuppression. Despite expanded use in cardiovascular and inflammatory conditions, there remains clinician concern because of potential myelosuppressive side effects. A systematic review was conducted to explore the reported myelosuppressive events of colchicine. Methods A systematic review was conducted using the…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet-
Research Article Examining the Characteristics of Colchicine-Induced Myelosuppression in Clinical Cases: A Systematic Review 📰 https://t.co/dzZItli8bH #myelosuppressive #colchicine #gout https://t.co/YRy7gncl8X
-
-
Mashup Score: 3potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes - 1 year(s) ago
Abstract. In type 1 diabetes, average life expectancy is reduced by more than 10 years as compared with outside of diabetes. Residual cardiovascular risk define
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
https://t.co/8Rp6F67Xpw New indication for #Colchicine ?
-
ICYMI: FDA approval of colchicine for coronary inflammation is expected to have a big impact on cardiac care and outcomes. #colchicine #atherosclerosis #pharma #cardiotwitter #cardiology #pharmacology https://t.co/fsOxCYe9Ji